NIH Ends Animal-Only Study Funding, Mandates New Approach Methodologies
Summary:
The NIH will no longer fund research proposals that rely exclusively on animal testing, instead requiring the integration of organoids, AI models, simulations, and organ-on-chip technologies.
Biopharma Navigates Regulatory Shifts While Advancing Key Therapies
Summary:
Despite policy upheaval under new HHS leadership, the industry achieves significant wins including Lilly’s oral obesity drug readout and rare disease approvals, shaping therapeutic landscapes.
FDA Streamlines CAR-T Cell Therapy Access Through Regulatory Reform
Summary:
Regulators remove burdensome safety requirements for blood cancer treatments, reducing hospital certification needs and expanding community access to life-saving immunotherapies.
Biotech Consolidation Accelerates as Cargo Therapeutics Joins Acquisition Wave
Summary:
CAR-T developer accepts $202 million buyout from Concentra Biosciences following failed lymphoma trial, highlighting industry’s ongoing restructuring amid challenging market conditions.
Trump Administration Targets Pharmaceutical Supply Chains with Massive Tariffs
Summary:
Planned 200% duties on drug imports signal major shift in trade policy, though one-year grace period allows industry time to adapt manufacturing strategies and supply chain operations.
AI Writing Tools Proliferate Across Biomedical Research Publications
Summary:
Analysis reveals one in seven research abstracts likely used artificial intelligence assistance, with distinctive vocabulary patterns emerging since ChatGPT’s widespread adoption in late 2022.
